eScholarship
metadata only
Incomplete Protection against Dengue Virus Type 2 Re-infection in Peru
BACKGROUND: Nearly half of the world's population is at risk for dengue, yet no licensed vaccine or anti-viral drug is currently available. Dengue is caused by any of four dengue virus serotypes (DENV-1 through DENV-4), and infection by a DENV serotype is assumed to provide life-long protection agai
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years#398189
- A Study of Dengue Tetravalent Vaccine (TDV) in Healthy Participants in Japan#174941
- Dengue vaccine acceptability in Peru: A mixed-methods study in two dengue-endemic Peruvian cities.#218933
- Acute-on-Chronic Liver Failure in a 13-Year-Old Patient With Wilson’s Disease Due to Dengue Virus Infection: A Case Report.#67439
- On a nonlocal dengue model with moving boundaries: The impact of dry-wet season and impulsive intervention#1035201
Record · ID 1379578
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive